Wave Life Sciences, Inc. (WVE): Total Assets
$638.50M
As of 2025-12-31
$558.32M
As of 2026-06-30
+63.4%
3-year compound annual growth
+18.0%
5-year compound annual growth
+14.5%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $638.50M | +81.3% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $352.21M | +28.1% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $274.95M | +87.8% | 2025-03-04, Balance as of period end |
| 2022-12-31 | $146.39M | -29.3% | 2024-03-06, Balance as of period end |
| 2021-12-31 | $207.01M | -25.9% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $279.24M | -1.8% | 2022-03-03, Balance as of period end |
| 2019-12-31 | $284.25M | -4.0% | 2021-03-04, Balance as of period end |
| 2018-12-31 | $295.94M | +62.7% | 2020-03-02, Balance as of period end |
| 2017-12-31 | $181.84M | +10.3% | 2019-03-01, Balance as of period end |
| 2016-12-31 | $164.81M | -0.4% | 2018-03-12, Balance as of period end |
| 2015-12-31 | $165.42M | n/m | 2017-03-16, Balance as of period end |
| 2014-12-31 | $2.94M | n/a | 2016-03-30, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $638.50M | +81.3% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $154.69M | +117.6% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $28.56M | +29.2% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $76.82M | +1.6% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $160.43M | +58.2% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $596.19M | +30.6% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $668.19M | -10.3% |
| BGM Group Ltd. (BGM) | 2025-09-30 | $433.81M | +718.5% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $172.25M | -45.4% |
Compare WVE, XLO, BFRI, CPIX side by side · Screen every company in Pharmaceutical Preparations ↗